This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CryoLife CEO Discusses Q3 2010 Results - Earnings Call Transcript

CryoLife Inc. ( CRY)

Q3 2010 Earnings Call

November 04, 2010 10:00 am ET


Steve Anderson - President and CEO

Ashley Lee - EVP, COO & CFO


Joe Munda - Sidoti

Tim Lee - Piper Jaffray

Matt Palmer - Roth Capital Partners

Raymond Myers - The Benchmark Company



Greetings, and welcome to the CryoLife’s third quarter 2010 financial conference call. Now at this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instruction). As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host Steve Anderson, President and CEO for CryoLife. Thank you. You may begin.

Steve Anderson

Good morning everyone. This is Steve Anderson, CryoLife’s President and CEO, and I would like to welcome you to CryoLife’s third quarter 2010 conference call. With me today is Ashley Lee, Executive Vice President, COO and CFO.

The agenda for today’s call is as follows. Actually we will review today’s press release and we’ll comment on the company’s revenues by product line. We will also bring you up to date on the litigation and dispute with Medafor. I will discuss the recent Starch Medical transaction, the rollout of BioFoam in Europe, the status of the BioFoam clinical trials of the US and the recent approval of BioGlue in Japan.

After my comments, Ashley will return with financial guidance for the rest of 2010 and our initial forecast for 2011. After Ashley’s forecast comments are completed we will open the call for questions. At this time Ashley will discuss this morning’s press release and the company’s performance for Q3.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs